Alzheimer’s Research Offers Doctors ‘Rightful Optimism’ on Care
- Unfamiliar feeling of hope permeates Boston medical conference
- Field has ‘momentum that I’ve never seen,’ researcher says
Eisai’s headquarters in Tokyo
Photographer: Akio Kon/BloombergThis article is for subscribers only.
Neurologists at the biggest Alzheimer’s research meeting in the US experienced something this week they hadn’t in years: optimism.
Just months after Eisai Co.’s Alzheimer’s drug Leqembi received full US approval, normally dour neurologists were buoyed by hints of easier-to-use therapies and the possibility of responding to the disease faster and on multiple fronts over the next few years.